Visa Insider Sold Shares Worth $11,148,872, According to a Recent SEC Filing-February 2024-www.financetom.com

Visa Insider Sold Shares Worth $11,148,872, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Visa Insider Sold Shares Worth $11,148,872, According to a Recent SEC Filing

Dec 13, 2024 1:34 PM

04:27 PM EST, 12/13/2024 (MT Newswires) -- Rajat Taneja, President, Technology, on December 12, 2024, sold 35,331 shares in Visa (V) for $11,148,872. Following the Form 4 filing with the SEC, Taneja has control over a total of 232,112 shares of the company, with 232,112 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1403161/000112760224029351/xslF345X05/form4.xml

Previous page： WNS Partners With Mosaic Insurance to Develop Future-Ready Operations Model Next page： ImmunityBio's Bladder Cancer Treatment Anktiva Launches in US

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

WNS Partners With Mosaic Insurance to Develop Future-Ready Operations Model

Jun 20, 2024

09:44 AM EDT, 06/20/2024 (MT Newswires) -- WNS Holdings ( WNS ) and Mosaic Insurance said Thursday that they partner to develop a future-ready operations model for underwriting and claims support, reinsurance processing, and finance and technology services. The companies said that the multi-year partnership will require WNS to digitize Mosaic's operations, integrate advanced analytics, and develop an automation hub...

ImmunityBio's Bladder Cancer Treatment Anktiva Launches in US

Jun 20, 2024

09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio ( IBRX ) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses. The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or...

Market Chatter: Tests Show Instagram Shares Sexual Videos to Accounts for 13-Year-Olds

Jun 20, 2024

09:44 AM EDT, 06/20/2024 (MT Newswires) -- Meta Platforms' ( META ) Instagram frequently recommends sexual videos to accounts for teenagers, The Wall Street Journal reported Thursday, citing separate tests conducted by it and Northeastern University computer science professor Laura Edelson. Similar tests for videos on Snapchat (SNAP) and TikTok did not produce the same sexualized content for underage users,...

Femasys Secures CE Mark Approvals for Four Women's Health Products; Shares Up Over 14%

Jun 20, 2024

09:45 AM EDT, 06/20/2024 (MT Newswires) -- Femasys ( FEMY ) said Thursday it received CE Mark certifications for four of its women's health products, certifying that the products comply with new European Union regulations for medical devices. The company said the CE Mark approvals come on the heels of the products' European Union Medical Device Regulation certificates and will...